NASDAQ:GALT - Galectin Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.97 +0.10 (+3.48 %) (As of 12/12/2019 04:00 PM ET) Add Compare Today's Range$2.81Now: $2.97▼$2.9950-Day Range$2.79MA: $3.48▼$4.2852-Week Range$2.74Now: $2.97▼$6.06Volume218,930 shsAverage Volume330,392 shsMarket Capitalization$168.95 millionP/E RatioN/ADividend YieldN/ABeta2.98 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GALT Previous Symbol CUSIPN/A CIK1133416 Webhttp://www.galectintherapeutics.com/ Phone678-620-3186Debt Debt-to-Equity RatioN/A Current Ratio41.51 Quick Ratio41.51Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-59.40Profitability EPS (Most Recent Fiscal Year)($0.38) Net Income$-13,900,000.00 Net MarginsN/A Return on Equity-51.23% Return on Assets-42.10%Miscellaneous Employees6 Outstanding Shares56,886,000Market Cap$168.95 million Next Earnings Date3/4/2020 (Estimated) OptionableOptionable Receive GALT News and Ratings via Email Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GALT Rates by TradingView Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions What is Galectin Therapeutics' stock symbol? Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT." How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. View Galectin Therapeutics' Earnings History. When is Galectin Therapeutics' next earnings date? Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Galectin Therapeutics. What price target have analysts set for GALT? 1 Wall Street analysts have issued 1 year target prices for Galectin Therapeutics' stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate Galectin Therapeutics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 270.4% from the stock's current price. View Analyst Price Targets for Galectin Therapeutics. What is the consensus analysts' recommendation for Galectin Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galectin Therapeutics. Has Galectin Therapeutics been receiving favorable news coverage? News headlines about GALT stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Galectin Therapeutics earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Galectin Therapeutics. Who are some of Galectin Therapeutics' key competitors? Some companies that are related to Galectin Therapeutics include Akero Therapeutics (AKRO), Omeros (OMER), Cara Therapeutics (CARA), Axovant Sciences (AXON), Vectura Group (VEGPF), Clovis Oncology (CLVS), TherapeuticsMD (TXMD), Kiniksa Pharmaceuticals (KNSA), Kadmon (KDMN), Basilea Pharmaceutica (BPMUF), AC Immune (ACIU), Retrophin (RTRX), BioDelivery Sciences International (BDSI), Phathom Pharmaceuticals (PHAT) and Cytokinetics (CYTK). What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX), Exelixis (EXEL), Intercept Pharmaceuticals (ICPT), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Rigel Pharmaceuticals (RIGL), Verastem (VSTM) and Immunomedics (IMMU). Who are Galectin Therapeutics' key executives? Galectin Therapeutics' management team includes the folowing people: Dr. Harold H. Shlevin, Pres & CEO (Age 69)Mr. Jack W. Callicutt, CFO & Sec. (Age 52)Robert Tritt, Gen. CounselDr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)Mr. J. Rex Horton, Exec. Director of Regulatory Affairs & Quality Assurance (Age 49) Who are Galectin Therapeutics' major shareholders? Galectin Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include D.A. Davidson & CO. (1.44%), State Street Corp (0.98%), California State Teachers Retirement System (0.11%), Wedbush Securities Inc. (0.04%), Squarepoint Ops LLC (0.02%) and Millennium Management LLC (0.02%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio, Gilbert S Omenn, Harold H Shlevin, Jack W Callicutt, James C Czirr, Joel Lewis, Kary Eldred, Kevin D Freeman, Marc Rubin, Peter G Traber, Richard E Uihlein and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics. Which institutional investors are selling Galectin Therapeutics stock? GALT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Wedbush Securities Inc.. Company insiders that have sold Galectin Therapeutics company stock in the last year include Fund LP 10X, Gilbert F Amelio and Marc Rubin. View Insider Buying and Selling for Galectin Therapeutics. Which institutional investors are buying Galectin Therapeutics stock? GALT stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, D.A. Davidson & CO., California State Teachers Retirement System and Squarepoint Ops LLC. Company insiders that have bought Galectin Therapeutics stock in the last two years include Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard E Uihlein. View Insider Buying and Selling for Galectin Therapeutics. How do I buy shares of Galectin Therapeutics? Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Galectin Therapeutics' stock price today? One share of GALT stock can currently be purchased for approximately $2.97. How big of a company is Galectin Therapeutics? Galectin Therapeutics has a market capitalization of $168.95 million. The company earns $-13,900,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe.View Additional Information About Galectin Therapeutics. What is Galectin Therapeutics' official website? The official website for Galectin Therapeutics is http://www.galectintherapeutics.com/. How can I contact Galectin Therapeutics? Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected] MarketBeat Community Rating for Galectin Therapeutics (NASDAQ GALT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 306 (Vote Outperform)Underperform Votes: 263 (Vote Underperform)Total Votes: 569MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe GALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2019 by MarketBeat.com StaffFeatured Article: What are economic reports?